Zimmer Biomet (ZBH) Expected to Release Earnings on Wednesday

Zimmer Biomet (NYSE:ZBH) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Zimmer Biomet to post earnings of $1.88 per share and revenue of $2.04 billion for the quarter. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the prior year, the business earned $2.07 earnings per share. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. On average, analysts expect Zimmer Biomet to post $8.54 EPS for the current fiscal year and $8.98 EPS for the next fiscal year.

Zimmer Biomet Stock Up 0.6%

ZBH stock opened at $96.66 on Wednesday. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $103.70. The company has a 50-day moving average price of $95.08 and a 200 day moving average price of $91.65.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, October 5th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $104.47.

Insider Activity

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Chad F. Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.28% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.